This option is evaluated based on individual needs and is always paired with ongoing medical oversight and lifestyle guidance
TRANSCEND-T2D-1 reported results on March 19, 2026 the first Phase 3 diabetes readout: These trials are expected to further broaden retatrutide's potential label across metabolic, musculoskeletal, and liver disease indications
While several peptides hold promise as adjuncts to knee OA treatment, BPC-157 is recognized as the single most effective peptide for knee OA pain and function
GHK-Cu is favored for skin, BPC-157 for recovery and gut health, CJC-1295 with Ipamorelin for body composition and sleep, and AOD-9604 or Tesamorelin for fat metabolism
Unlike traditional diabetes medications that target only blood sugar, Tirzepatide 15mg works on multiple pathways, providing dual benefits of glycemic control and weight management
Bioinformatics of RNA Editing in Dendritic Cells